SCHEMBL1685157

SCHEMBL1685157

O=C1NCc2cc(-c3ccc(Nc4ccc(S(=O)(=O)NC5CCNC5)cc4)c4nccn34)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 3/20 0.46
NAMPT P43490 1/20 0.37
HDAC4 P56524 1/20 0.37
KDR P35968 1/20 0.35
GSK3B P49841 1/20 0.34
IKBKB O14920 3/20 0.34
CHUK O15111 2/20 0.34
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
MKNK1 Q9BUB5 2/20 0.33
EIF4E P06730 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
TBK1 Q9UHD2 1/20 0.33
JAK2 O60674 1/20 0.32
ROCK2 O75116 1/20 0.32
JAK1 P23458 1/20 0.32
TYK2 P29597 1/20 0.32
JAK3 P52333 1/20 0.32
ROCK1 Q13464 1/20 0.32
TARS1 P26639 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12653072 0.86 MAPKAPK5 (0.44) MAPKAPK5NAMPTHDAC4KDRIKBKB
SCHEMBL10165985 0.85 MAPKAPK5 (0.46) MAPKAPK5GSK3BMKNK1EIF4EMKNK2
SCHEMBL1685196 0.85 MAPKAPK5 (0.51) MAPKAPK5GSK3BMKNK1MKNK2TBK1
SCHEMBL4399427 0.85 MAPKAPK5 (0.45) MAPKAPK5NAMPTGSK3BMKNK1EIF4E
SCHEMBL1792559 0.85 MAPKAPK5 (0.47) MAPKAPK5HDAC4GSK3BIKBKBMKNK1
SCHEMBL13937607 0.84 MAPKAPK5 (0.46) MAPKAPK5GSK3BMKNK1EIF4EMKNK2
SCHEMBL10166873 0.84 MAPKAPK5 (0.53) MAPKAPK5GSK3BIKBKBCHUKMKNK1
SCHEMBL10134756 0.84 MAPKAPK5 (0.53) MAPKAPK5GSK3BMKNK1EIF4EMKNK2
SCHEMBL1685321 0.84 MAPKAPK5 (0.53) MAPKAPK5GSK3BIKBKBCHUKMKNK1
SCHEMBL1685332 0.82 MAPKAPK5 (0.51) MAPKAPK5GSK3BMKNK1EIF4EMKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
EP-2099798-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES Galapagos N.V. (BE) 2009-09-16 EP disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
WO-2008065199-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-05 WO disclosed
WO-2008065199-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885NAMPT 526/4885HDAC4 920/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885NAMPT 526/4885HDAC4 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.